Andere talen Supernus Pharmaceuticals, Inc.

Aandelen

SUPN

US8684591089

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
30,6 ^USD	+1,76%		+3,00%	+5,74%

08/04	Supernus' medicijnaanvraag voor Apomorfine-pomp voor Parkinson ondervindt tegenslag van FDA; aandelen dalen Premarket	MT
08/04	Supernus Pharmaceuticals, Inc. kondigt een regelgevende update aan voor SPN-830	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors	01:21
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN	28/04
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024	24/04
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN	20/04
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	08/04
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	08/04
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	08/04
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	08/04
Supernus Provides Regulatory Update for SPN-830	08/04
Supernus Provides Regulatory Update for SPN-830	08/04
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	25/03
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	21/03
Supernus to Participate in Two Upcoming Investor Conferences	06/03
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference	28/02
Supernus: Q4 Earnings Snapshot	28/02
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023	27/02
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	27/02
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	27/02
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Supernus Pharmaceuticals, Inc.

Aandelen

SUPN

US8684591089

Andere talen

Filters